Here’s a startling fact: treating all blocked arteries during a heart attack, not just the one causing the immediate crisis, could be the difference between life and death. But here’s where it gets controversial—while this approach, known as complete revascularization, has been debated for years, a groundbreaking international study now confirms its life-saving potential. Led by researchers at the Population Health Research Institute (PHRI), a collaborative effort between McMaster University and Hamilton Health Sciences, this study reveals that opening all blocked arteries with stents significantly reduces the risk of death from cardiovascular causes, death from any cause, and future heart attacks compared to treating only the culprit artery.
Published in The Lancet and presented at the American Heart Association’s 2025 Scientific Sessions, the findings shed new light on a dilemma cardiologists often face: should they focus solely on the artery causing the acute heart attack, or should they address all blockages? And this is the part most people miss—while previous trials hinted at the benefits of complete revascularization for non-fatal heart events, its impact on reducing cardiovascular deaths, the most critical outcome, remained unclear. By pooling data from six large international trials involving 8,836 patients, researchers finally provided a definitive answer.
Over a three-year follow-up, patients who underwent complete revascularization saw a 24% relative reduction in cardiovascular deaths and a 15% reduction in all-cause deaths compared to those treated only for the culprit artery. Specifically, cardiovascular death rates dropped from 4.6% to 3.6%, and new heart attacks decreased from 11.5% to 9.0%. These benefits were consistent across patients with both major (STEMI) and minor (NSTEMI) heart attacks, as well as across age groups. Importantly, these improvements were observed alongside standard heart treatments like blood thinners, statins, and beta-blockers.
Here’s the bold part: complete revascularization isn’t just about preventing future heart attacks—it’s about prolonging life. As study chair Shamir R. Mehta puts it, this procedure now stands as one of the few life-saving interventions cardiologists have that can both prevent recurrent heart attacks and extend survival. That’s a game-changer with far-reaching implications for patient care.
But let’s pause for a moment—is this approach always the best choice? While the data is compelling, some may argue that treating all blockages could increase procedural risks or costs. What do you think? Should complete revascularization become the standard of care for heart attack patients, or are there valid reasons to proceed with caution? Share your thoughts in the comments—this is a conversation worth having.
